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Ouabain prevents pathological 
cardiac hypertrophy and heart failure 
through activation of phosphoinositide 3-kinase 
α in mouse
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Abstract 
Background: Use of low doses of digitalis to prevent the development of heart failure was advocated decades ago, 
but conflicting results of early animal studies dissuaded further research on this issue. Recent discoveries of digitalis 
effects on cell signal pathways prompted us to reexamine the possibility of this prophylactic action of digitalis. The 
specific aim of the present study was to determine if subinotropic doses of ouabain would prevent pressure overload-
induced cardiac remodeling in the mouse by activating phosphoinositide 3-kinase α (PI3Kα).
Results: Studies were done on an existing transgenic mouse deficient in cardiac PI3Kα (p85-KO) but with normal car-
diac contractility, a control mouse (Con), and on cultured adult cardiomyocytes. In Con myocytes, but not in p85-KO 
myocytes, ouabain activated PI3Kα and Akt, and caused cell growth. This occurred at low ouabain concentrations that 
did not activate the EGFR-Src/Ras/Raf/ERK cascade. Con and p85-KO mice were subjected to transverse aortic con-
striction (TAC) for 8 weeks. A subinotropic dose of ouabain (50 µg/kg/day) was constantly administrated by osmotic 
mini-pumps for the first 4 weeks. All mice were monitored by echocardiography throughout. Ouabain early treatment 
attenuated TAC-induced cardiac hypertrophy and fibrosis, and improved cardiac function in TAC-operated Con mice 
but not in TAC-operated p85-KO mice. TAC downregulated α2-isoform of Na+/K+-ATPase but not its α1-isoform in Con 
hearts, and ouabain treatment prevented the downregulation of α2-isoform. TAC-induced reduction of α2-isoform did 
not occur in p85-KO hearts.
Conclusions: Our results show that (a) safe doses of ouabain prevent or delay cardiac remodeling of pressure 
overloaded mouse heart; and (b) these prophylactic effects are due to ouabain binding to α2-isoform resulting in the 
selective activation of PI3Kα. Our findings also suggest that potential prophylactic use of digitalis for prevention of 
heart failure in man deserves serious consideration.
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Background
In 1933, Christian [1] advocated the prophylactic use of 
digitalis to retard cardiac enlargement in patients with 
heart disease but without heart failure. In 1965, Wil-
liams and Braunwald [2] presented the first experimental 
support for this proposal showing that rats subjected 
to suprarenal aortic constriction and treated with daily 
nontoxic doses of digitoxin prior and following aortic 
constriction, exhibited less myocardial hypertrophy and 
lower incidence of fatal heart failure than rats subjected 
to aortic constriction but not treated with digitoxin. 
Though a number of studies that followed [3–5] either 
confirmed or questioned the above findings and conclu-
sions, the issue of whether or not digitalis has a prophy-
lactic effect on the growth of the overloaded hearts seems 
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to have disappeared from the subsequent literature. Per-
haps the question was raised ahead of its time. We have 
now reexamined the issue in the light of the recently 
appreciated effects of digitalis drugs on cell signaling 
pathways. Here, we present the results of initial studies 
using fresh experimental approaches to test for the pos-
sible prophylactic effect of digitalis on the heart that is 
subjected to pressure overload.
Digitalis drugs (such as digoxin, digitoxin, and oua-
bain) are highly specific inhibitors of the Na+/K+-ATPase 
of the plasma membrane of most of higher eukaryotic 
cells [6, 7]. This enzyme (the sodium pump) catalyzes 
the coupled active transport of Na+ and K+, maintains 
resting membrane potential, regulates cell volume, and 
enables the Na+-coupled transports of a multitude of 
nutrients and other ions across the cell membrane. Na+/
K+-ATPase has two subunits (α and β) that are essential 
for ion pumping, and a third subunit (a FXYD protein) 
that regulates function [6, 7]. There are multiple isoforms 
of each subunit with tissue and species specificities, and 
variations among the digitalis sensitivities of the isoforms 
[6–8].
In the heart, digitalis concentrations that partially 
inhibit Na+/K+-ATPase to cause a modest increase in 
intracellular Na+ are sufficient to affect the robust Na+/
Ca2+ exchanger of the myocyte plasma membrane, caus-
ing significant increases in intracellular Ca2+ and cardiac 
contractility [9, 10]. This positive inotropic effect has long 
been assumed by many to be the basis of the classical use 
of digitalis drugs for the treatment of heart failure [9, 10].
In more recent years, it has been realized that in addi-
tion to its vital ion transport function, Na+/K+-ATPase 
may also act as a signal transducer. Through digitalis-
induced transient communications with neighbor-
ing membrane proteins, the digitalis-inhibited Na+/
K+-ATPase activates multiple cell signaling pathways, 
leading to highly cell-specific downstream consequences 
[11]. In our early studies on the signaling function of the 
sodium pump in cardiac myocytes, we noted the appar-
ent paradox that digitalis drugs which had long been 
used to treat the hypertrophied failing heart, caused 
hypertrophy of the cultured cardiac myocytes [12]. Sub-
sequently, we found that this drug-induced hypertrophy 
is due to the activation of PI3K/Akt/mTOR pathway, and 
that digitalis treatment of the cultured myocytes activates 
PI3Kα but not PI3Kγ [13]. More recently, we also showed 
that ouabain-induced activation of PI3Kα and the result-
ing hypertrophy are independent of ouabain’s positive 
inotropic effect [14]. These findings, coupled with the 
extensive prior research of others [15] indicating the 
association of PI3Kα with physiological cardiac hyper-
trophy, and that of PI3Kγ with pathological hypertrophy, 
led us to suspect that digitalis-induced hypertrophy may 
indeed be akin to physiological hypertrophy [13, 14]. 
And since there is ample evidence to suggest that selec-
tive activation of PI3Kα not only induces physiological 
hypertrophy but may also prevent the detrimental effects 
of the stimuli that cause pathological hypertrophy [15], 
we hypothesized that the forgotten prophylactic effect 
of digitalis is due to the selective activation of cardiac 
PI3Kα. Here, we report the testing of this hypothesis 
in the mouse. We used ouabain as prototypic digitalis 
drug; transverse aortic constriction (TAC) to induce 
pressure-overload and pathological hypertrophy; and we 
compared the effects of ouabain treatment on the devel-
opment and the consequences of TAC in the wild type 
mouse and a genetically modified mouse from which 
cardiac PI3Kα was deleted but exhibited normal cardiac 
contractility and histology [16]. Our findings supported 
the tested hypothesis.
Results
Comparison of heart size and function in normal mice 
and those deficient in PI3Kα
In the present studies, which were designed to test our 
hypothesis on the prophylactic action of ouabain, we 
wished to use the mouse generated by Luo et al. [16] with 
the muscle specific deletion of p85α regulatory subu-
nit and germ line deletion of p85β regulatory subunit 
of PI3Kα. Because this mouse has not been widely used 
since its generation, we deemed it necessary to confirm 
their main findings on the characteristics of this mouse. 
Our results summarized below are consistent with and 
reinforce those of Luo et  al. [16]: (1) In the p85-KO 
mouse, relative to Cre mice (Control mice), protein lev-
els of p85α and p110α of PI3Kα were greatly reduced in 
the lysates of the whole heart or the isolated cardiomy-
ocytes, whereas the levels of p110γ of PI3Kγ remained 
unchanged (Fig.  1a); (2) in cardiomyocyte lysates of the 
p85-KO mouse, relative to those of the control, the basal 
level of PI3Kα activity was greatly reduced, while the 
activity of PI3Kγ was unchanged (Fig.  1b). The remain-
ing 10 % of the PI3Kα activity in the lysate of the p85-KO 
myocytes is most likely due to myocytes that have 
escaped gene deletion as noted before [16], and as it has 
been established in cases of many other cardiac-specific 
deletions [14, 17]; (3) when intact cardiomyoyctes iso-
lated from the p85-KO and the control mice were simi-
larly exposed to insulin, the expected activation of Akt 
was noted in the control myocytes, but greatly reduced 
in the p85-KO myocytes (Fig.  1c). The serine/threonine 
kinase Akt, also known as protein kinase B (PKB), is a 
downstream component of the signaling cascades that 
are dependent on PI3 K activation at the insulin or other 
growth factor receptors [15, 16]; (4) The hearts of the 
p85-KO mice were smaller than those of control (Fig. 1d; 
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Table 1), but cardiac contractility and function seemed to 
be normal in the KO hearts (Tables 1, 2).
Comparison of Ouabain’s signaling effects 
on cardiomyocytes isolated from normal mice and those 
deficient in PI3Kα
Adult mouse cardiomyocytes are known to contain the 
α1 isoform, the α2 isoform, and the β1 isoform of the 
Na+/K+-ATPase [14, 18]. Since an αβ dimer is the func-
tional unit to which ouabain binds [7], we immunoas-
sayed the lysates of freshly isolated cardiomyocytes of the 
control and the p85-KO mice for α1, α2, and β1 protein, 
and found no significant differences between the isoform 
content in the two mice (Fig. 2a).
Our previous studies indicating ouabain-induced 
selective activation of cardiac PI3Kα but not PI3Kγ [13] 
were done on neonatal and adult cardiomyocytes of rat. 
To see if similar selective effects of ouabain are noted in 
adult mouse cardiomyocytes, intact myocytes isolated 
from control and p85-KO mouse hearts were exposed 
to ouabain for 5 min, and assayed for PI3Kα and PI3Kγ 
activity. In control myocytes, ouabain activated PI3Kα 
but not PI3Kγ activity (Fig.  2b). Ouabain also caused 
no significant activation of PI3Kγ of the p85-KO myo-
cytes (Fig.  2b). Consistent with these findings, ouabain-
induced activation of Akt during 5–15 min was observed 
in the control myocytes (Fig. 2c), but not in p85-KO myo-
cytes (Fig. 2d). When further experiments were done to 
estimate the minimum dose of ouabain necessary for 
the rapid activation of Akt in control myocytes, ouabain 
concentration as low as 5 nM caused pronounced activa-
tion of Akt after 5 min treatment (Fig. 2e). Significantly, 
the activation of ERK 1/2 in the same control myocytes 
required much higher ouabain concentrations (Fig. 2f ).
In isolated cardiomyocytes, hypertrophy of the termi-
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Fig. 1 Characterization of p85-KO mouse hearts. a. Representative blots of p110α and p85 subunits of PI3Kα and p110 γ subunit of PI3Kγ in whole 
heart lysate (top left) and in freshly isolated adult mouse cardiomyocytes (top right). GAPDH was used as a loading control. Quantitative data of 
expression of PI3 K subunits in Con and p85-KO mouse hearts (n = 4) (bottom left) and cardiomyocytes (n = 7) (bottom right); b representative TLC 
plates show PI3Kα and PI3Kγ lipid kinase activities in freshly isolated Con or p85-KO cardiomyocytes (top). Quantitative data of PI3K activity in Con 
and p85-KO cardiomyocytes (n = 4); c insulin (100 nM)- induced Akt signaling in Con and p85-KO cardiomyocytes (representative blots of three 
experiments) and d comparison of body weight, heart weight and left ventricular weight in Con and p85-KO mice (Con n = 5, p85-KO n = 7). 
*P < 0.05, **P < 0.01 vs. Con
Page 4 of 15Wu et al. Cell Biosci  (2015) 5:64 
the initial rate of protein synthesis [19, 20], and we have 
shown before that ouabain-induced activation of PI3Kα/
Akt pathway leads to increase protein synthesis in isolated 
mouse adult cardiomyocytes [14]. Comparing protein 
synthesis in the control and the p85-KO myocytes, we 
found that ouabain (50 μM, 12 h) stimulated hypertrophy 
significantly in the former but not in the latter (Fig. 3a). 
Importantly, endothelin-1 (ET-1) which is known to cause 
pathological hypertrophy through the activation of PI3Kγ 
[15], increased protein synthesis in both the control and 
the p85-KO myocytes (Fig. 3a). Atrial natriuretic peptide 
(ANP), brain natriuretic peptide (BNP) and β-myosin 
heavy chain (β-MHC) are commonly used cardiac hyper-
trophic markers [15]. In agreement with our previous 
findings [14], and consistent with the present findings of 
Fig.  3a, ET-1 (100  nM, 12  h) stimulated the expression 
of BNP in both myocytes, while ouabain had no signifi-
cant effect on BNP expression in either the control or the 
p85-KO myocytes (Fig. 3b, c).
In separate experiments, we examined the effects of 
ouabain, ET-1, and the combination of the two on protein 
synthesis in control cardiomyocytes. The results (Fig. 3d) 
are consistent with the proposition that ouabain-induced 
hypertrophy antagonizes ET-1-induced hypertrophy at 
the cellular level.
Assessing the prophylactic effect of ouabain 
on TAC‑induced cardiac hypertrophy and dysfunction 
in normal mice and those deficient in PI3Kα
Supported by the above findings at the cellular level, the 
aims of the following in vivo experiments were to deter-
mine if treatment of mice with low doses of ouabain 
could prevent or delay the known TAC-induced cardiac 
dysfunction and failure; and if so, whether or not such 
ouabain effects were dependent on PI3Kα.
TAC - caused chronic changes were monitored over 
a period of 8 weeks. To assess ouabain effects, the drug 
was infused subcutaneously (50  μg/kg/day) by ALZET 
osmotic pump for continuous dosing during the first 
4  weeks. In these experiments, ouabain concentration 
in circulating blood in heart is dependent on its absorp-
tion, distribution, metabolism and excretion. We chose 
the indicated dosage regimen based on previous find-
ing of others [21] and our data of Fig. 3a in order to keep 
serum concentrations of ouabain at low nM range (see 
Discussion).
Because of previous disagreements on whether or not 
ouabain affects blood pressure in rodents [21, 22], it was 
necessary to determine the effect of long-term infusion of 
ouabain on systemic blood pressure in our studies. Tail-
cuff blood pressure measurements showed no significant 
ouabain effects in sham or TAC groups from the control 
or the p85-KO mice (Additional file 1: Fig. S1). Evidently, 
ouabain effects on systemic blood pressure are peculiar 
to rats but not mice as also noted before by others [21].
Echocardiographic analysis showed that posterior wall 
thickness, septal wall thickness and relative wall thick-
ness increased during the first 2 weeks after TAC in the 
control and the p85-KO mice; however, ouabain pre-
vented the TAC-induced increase of wall thickness in the 
control but not in the p85-KO mice (Fig. 4). Echocardiog-
raphy also showed that left ventricular chambers began 
to dilate after six weeks of TAC in both the control and 
the p85-KO mice; the effect being especially prominent 
Table 1 Echocardiographic analysis (baseline) of Con and p85-KO mouse hearts
The p85-KO and the Cre controls (12–16 week-old, male) were subjected to echocardiography analysis
BW body weight; HR heart rate; EDA end diastolic area; ESA end systolic area; PWT posterior wall thickness; SWT septal wall thickness; RWT relative wall thickness; MPI 
myocardial performance index; FS fractioning shortening; LV mass left ventricular mass; Con n = 21; KO n = 15
* p < 0.05 v.s. Con
BW (g) HR (bpm) EDA (cm2) ESA (cm2) PWT (cm) SWT (cm) RWT MPI FS LV mass (g)
Con 31.8 ± 1.2 439 ± 9 0.168 ± 0.004 0.088 ± 0.003 0.114 ± 0.003 0.104 ± 0.003 0.60 ± 0.02 0.36 ± 0.03 0.45 ± 0.02 0.126 ± 0.004
KO 28.4 ± 1.0 438 ± 11 0.153 ± 0.004* 0.081 ± 0.004 0.108 ± 0.005 0.087 ± 0.002* 0.54 ± 0.02 0.30 ± 0.02 0.45 ± 0.01 0.105 ± 0.005*
Table 2 Comparison of cardiac hemodynamic function (baseline) of Con and p85-KO mouse hearts
Hemodynamic function of p85-KO and the Cre controls (12 week-old, male) were measured by cardiac catheter as described in “Method”. There is no statistical 
significance between the Con and KO mice
BW body weight; HR heart rate; Ves end systolic volume; Ved end diastolic volume; Pes end systolic pressure; Ped end diastolic pressure; SV stroke volume; EF ejection 
fraction; +dP/dt the rate of pressure development; −dP/dt the rate of relaxation. Con n=4; KO n=7
BW (g) HR (bpm) Ves (LII) Ved (LII) Pes (mmHg) Ped (mmHg) SV (Lll) EF (%) dP/dt (mmHg/s) −dP/dt (−mm Hg/s)
Con 23.1 ± 3.0 339 ± 32 14.8 ± 2.3 22.2 ± 1.2 79.2 ± 5.6 7.0 ± 2.7 10.2 ± 1.7 48.3 ± 8.4 4452 ± 924 3998 ± 858
KO 21.3 ± 1.8 271 ± 11 12.5 ± 2.0 17.8 ± 2.4 75.3 ± 1.8 6.5 ± 1.4 7.9 ± 1.1 44.4 ± 5.9 3732 ± 385 3092 ± 444
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in the end-systolic dimension (Fig.  5). The early treat-
ment with ouabain during the first 4 weeks significantly 
reduced this TAC-induced dilation of left ventricles in 
the control but not the p85-KO mice (Fig. 5). TAC also 
reduced contractile function (Fractional shortening, 
FS %) four weeks after surgery in both the control and the 
p85-KO mice; and ouabain pretreatment rescued cardiac 
dysfunction in the control but not the KO mice (Fig. 6a, 
b). Myocardial Performance Index (MPI) generated from 
pulsed wave Doppler imaging was employed to further 
examine systolic and diastolic functions. In line with the 
FS  % results, the early treatment with ouabain partially 
improved cardiac function in the control but not in the 
p85-KO mice (Fig. 6c, d).
Postmortem analyses performed after 8 weeks of TAC 
showed that: (1) Ouabain pretreatment significantly 
attenuated the TAC-induced cardiac hypertrophy in the 
control mice but not the KO mice (Fig.  7a); (2) cardiac 
fibrosis measured by trichrome staining, which was evi-
dent in all TAC hearts was significantly reduced by oua-
bain pretreatment in the control but not the p85-KO 
hearts (Fig.  7b). We also measured peri-vascular fibro-
sis in all groups and observed results similar to those of 
Fig.  7b (data not shown); (3) the TAC-induced effects 
on ANP and BNP mRNA expressions noted in both the 
control and the KO mice were antagonized by ouabain 
pretreatment in the control but not the p85-KO hearts 
(Fig. 7c).
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Fig. 2 Comparison of ouabain-induced signaling in cultured cardiomyocytes from Con and p85-KO mice. a. Representative blots of Na+/K+-ATPase 
isoforms (top). GAPDH was used as a loading control. Quantitative data of expression of Na+/K+-ATPase isoforms (n = 6) (bottom); b. representative 
PI(3)P dots show the effect of ouabain (50 μM, 5 min) on PI3Kα and PI3Kγ lipid kinase activities in Con and p85-KO cardiomyocytes, vehicle (vehi) 
(top). Quantitative data of PI3K activity from the top. (n = 9, *P < 0.05 vs. vehi); c representative blots of the effect of ouabain on Akt activation in 
Con cardiomyocytes (top). Quantitative data of Akt activation from the top (n = 6, *P < 0.05 vs. vehi); d representative blots of the effect of ouabain 
on Akt activation in p85-KO cardiomyocytes (top). Quantitative data of Akt activation from the top. (n = 6, *P < 0.05 vs. vehi). e ouabain (5 min) 
dose- responses on Akt activation in wild-type cardiomyocytes (n = 6, *P < 0.05, **P < 0.01 vs. vehi) and f ouabain (5 min) dose- responses on ERK 
activation in wild-type cardiomyocytes (n = 6, *P < 0.05 vs. vehi)
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Taken together, the above in  vivo findings provide 
strong support for the existence of a prophylactic effect 
of ouabain on TAC-induced cardiac hypertrophy and the 
subsequent cardiac dysfunction; and indicate that this 
ouabain effect is dependent on the presence of PI3Kα in 
the heart.
Because of the longstanding prior findings indicating 
that the α2-subunit of the rat cardiac Na+/K+-ATPase, 
but not that of the α1-subunit, may be transcriptionally 
down-regulated by pressure overload [23, 24], we also 
looked for changes in the mRNA and protein levels of the 
α-subunits in the postmortem hearts of the experiments 
of Fig. 7. In the control mouse hearts, TAC significantly 
reduced α2 mRNA and protein levels, but did not alter 
the protein level of the α1-subunit (Fig. 8a, c). In the con-
trol mouse treatment with ouabain for the first 4 weeks, 
the TAC effect on the protein level of the α2 was clearly 
antagonized by ouabain, though a significant ouabain 
effect on the α2 mRNA was not detected (Fig. 8a, c). Con-
sistent with the lack of effect of TAC on the expression of 
the α1-subunit, ouabain treatment also did not affect the 
expression of α1 protein in the control hearts (Fig.  8a). 
In the p85-KO mouse hearts, neither TAC nor TAC with 
ouabain treatment had significant effects on α2 mRNA 
and α1 and α2 protein levels relative to those of sham-
operated mice (Fig. 8b, d).
Taken together, the findings of Fig.  8 clearly indicate 
the previously unrecognized fact that PI3Kα is required 
for the downregulation of the α2 isoform of cardiac Na+/
K+-ATPase. Though previous studies [23, 24] showed 
that TAC effects on α2 are transcriptional, we showed the 
possibility that ouabain may prevent degradation or alter 
the translational efficiency of α2 isoform of cardiac Na+/
K+-ATPase.
Discussion
The decisive part of these studies that establish the pro-
phylactic effect of ouabain on pressure overload-induced 
hypertrophy are the results of the in  vivo experiments 


































































































































Fig. 3 Effects of ouabain on hypertrophic growth and hypertrophic marker gene expressions in cultured cardiomyocytes of Con and p85-KO mice. 
a Comparison of 12 h treatment of ouabain (50 μM) and ET-1 (100 nM) on protein synthesis (3H-leucine incorporation) in Con and p85-KO cardio-
myocytes (n = 6); b, c ouabain and ET-1 effects on hypertrophic markers (fetal gene expression) in Con and p85-KO cardiomyocytes (n = 3) and d 
effects of ouabain, ET-1 and the combination of the two on protein synthesis (3H-phenylalanine incorporation) (n = 9). *P < 0.05 vs. vehi, **P < 0.01 
vs. vehi, #P < 0.05 vs. oua
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PI3Kα. These studies, however, would not have been 
attempted had we not done our initial experiments on 
the isolated cultured myocytes. It is necessary, therefore, 
to begin with the discussion of the important aspects of 
the in vitro studies.
Selective activation of PI3Kα by ouabain and its effects 
on the hypertrophy of cardiomyocytes
At the cellular level, cardiac hypertrophy is accompa-
nied by the increased size of the cardiac myocytes most 
of which have little or no capacity to proliferate [25]. In 
our previous studies on isolated mouse myocytes [26], we 
showed that the hypertrophy of these cells as measured 
by increase in protein synthesis is stimulated by ouabain 
through the activation of PI3Kα/Akt cascade, but we 
had no direct evidence that the ouabain-activated PI3K 
was the PI3Kα. Our present findings now demonstrate 
that only PI3Kα but not PI3Kγ is activated by ouabain 
(Fig. 2b); and that only in control myocytes but not those 
deficient in PI3Kα, there is ouabain-induced activation of 
Akt resulting in hypertrophy (Figs. 2c, d, 3c).
Our ability to study stimulus-induced hypertrophy 
in isolated adult cardiomyocytes of mice allowed us to 
ask if the ouabain-induced selective activation of PI3Kα 
could antagonize cellular hypertrophy induced by a 
selective activator of PI3Kγ such as ET-1. Our experi-
ments showed that even in these in vitro studies ouabain 
seemed to reduce ET-1-stimulated hypertrophy (Fig. 2f ). 
In spite of the obvious limitation of these in vitro experi-
ments, their results clearly encouraged the conduct of 
our subsequent in vivo studies.
The most important part of our findings on the cul-
tured myocytes that allowed us to proceed to the in vivo 
experiments was the data showing the great sensitivity of 
Con



































































































































































Fig. 4 Effects of ouabain on TAC-induced cardiac hypertrophy in Con and p85-KO mice. Experiments were done as described in “Methods”. Left 
ventricular wall thickness was monitored by echocardiography before and after 8 weeks of the surgery. Ouabain was infused subcutaneously 
(50 μg/kg/day) by ALZET osmotic pumps for continuous dosing for the first 4 weeks. a Posterior wall thickness (PWT); b septal wall thickness (SWT) 
and c relative wall thickness (RWT). n = 6 ~ 7, *P < 0.05 vs. Sham; #P < 0.05 vs. TAC
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PI3Kα/Akt pathway to ouabain concentrations as low as 
5 nM (Fig. 2e). This clearly suggested the feasibility of the 
more onerous in vivo studies. Previous studies of others 
[21] had indicated that the repeated daily administration 
of 300 μg/kg of ouabain to mice resulted in extracellular 
levels of 3.3 nM of “ouabain-like” immune-reactive mate-
rial and no evident toxicity. It had also been shown that 
in wild-type mouse hearts, the first evidence of positive 
inotropic effect is noted at about 40  nM ouabain [27]. 
Based on this information and our data of Fig.  2e, we 
chose to use the daily dose of 50 μg/kg of ouabain in our 
in vivo experiments (Figs. 4, 5, 6, 7, 8) to ensure that oua-
bain regimen is subinotropic and nontoxic. The results 
of our in vivo experiments proved that we had made the 
right choice.
In relation to the very high sensitivity of the PI3Kα/Akt 
pathway to ouabain (Fig.  2e), it is important to empha-
size the contrasting low ouabain sensitivity of the path-
way that leads to ERK1/2 activation (Fig.  2f ). Although 
our previous studies [11, 13, 14] had shown that in adult 
cardiac myocytes two parallel cell signaling cascades; i.e., 
EGFR-Src/Ras/Raf/ERK and PI3Kα/Akt are function-
ally linked to the ouabain-inhibited Na+/K+-ATPase, we 
had not tested a wide range of ouabain concentration 
on these pathways before. The present findings (Fig. 2e, 
f ) showing about two orders of magnitude of difference 
in the sensitivities of these cascades in the adult mouse 
myocytes suggest that each of these cascades is linked 
to a different ouabain binding site. And since the two 
known α-subunits of these myocytes do indeed have oua-
bain sensitivities of about 2–3 orders of magnitude apart 
[18, 27], it is reasonable to conclude that the EGFR-Src/
Ras/Raf/ERK cascade is functionally linked to the insen-
sitive α1-isoform, and that the PI3Kα/Akt is functionally 
linked to the sensitive α2-isoform. This conclusion also 
fits the previously observed irrelevance of the EGFR-Src/
Ras/Raf/ERK pathway to ouabain-induced hypertrophy 
of the mouse cardiomyocytes [14].
Prevention of pressure overload‑induced cardiac 
dysfunction by treatment with a nontoxic dose of ouabain
The major findings of our in vivo studies and their impli-
cations are rather straightforward. In both the control 
mice and those deficient in cardiac PI3  Kα, a standard 
protocol of TAC produced compensated hypertrophy 
during the first 4  weeks, followed by decompensated 
hypertrophy and failure during the next 4  weeks; and 
ouabain treatment during the first 4 weeks clearly antag-
onized TAC-induced cardiac dysfunction in control mice 
but not in those deficient in cardiac PI3Kα (Figs. 4, 5, 6, 
Con





















































































































Fig. 5 Effects of ouabain on TAC-induced chamber dilation in Con and p85-KO mice. Experiments were done as described in “Methods”. Left 
ventricular chamber size was monitored by echocardiography before and after 8 weeks of the TAC or sham surgery. Ouabain was infused subcuta-
neously (50 μg/kg/day) by ALZET osmotic pumps for continuous dosing for the first 4 weeks. a End diastolic dimension (EDD); b end systolic dimen-
sion (ESD). n = 6 ~ 7, *P < 0.05 vs. Sham; #P < 0.05 vs. TAC
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7). In short, our in vivo studies agreed with the findings 
of Williams and Braunwald [2] regarding the prophylac-
tic effect of digitalis on the hypertrophy of the pressure 
overloaded heart. The major difference between the two 
studies done nearly half century apart is that they used 
rats and digitoxin but we have used mice and ouabain.
Our studies provide a wealth of new information on the 
mechanistic bases of the above prophylactic effect of oua-
bain. The most important being that the absence of this 
prophylactic effect in hearts deficient in PI3  Kα estab-
lishes the hypothesis that it is the selective activation of 
this lipid kinase isoform that opposes the detrimental 
effects of the various cell signaling cascades that are acti-
vated by pressure overload on the heart [13, 15].
Another important mechanistic issue revealed by our 
findings is the identification of the α2 isoform of Na+/
K+-ATPase as the likely partner of the PI3Kα for exerting 
and regulating ouabain’s prophylactic effect on the over-
loaded heart. It is the responsiveness of the PI3Kα/Akt 
pathway to low nM ouabain concentrations that clearly 
implicates the α2-isoform in a functional interaction 
with PI3Kα resulting in prevention of the hypertrophy. 
In addition, since pressure-overload down-regulates the 
α2 isoform and ouabain reverses this (Fig. 8a, c), it seems 
that there is a second distinct role of ouabain-inhibited 
α2-isoform: Saving the α2-isoform from disappearance 
due to overload-induced transcriptional downregulation. 
The fact that in hearts deficient in PI3Kα neither the over-
load-induced downregulation of the α2-isoform, nor the 
ouabain-induced reversal of this are observed (Fig. 8b, d) 
clearly indicate that PI3Kα must also be involved in the 
transcriptional downregulation of the cardiac α2 isoform 
of Na+/K+-ATPase. The mechanism of this novel action 
of PI3Kα remains to be studied. A scheme summarizing 
the above conclusions is presented in Fig. 9.
It is appropriate to note that other recent evidence 
has also implicated the cardiac α2 isoform of Na+/K+-
ATPase in regulation of cardiac hypertrophy. There is an 
extensive history of research suggesting the special role 
of the digitalis-sensitive but quantitatively minor α2 iso-
form in the regulation of intracellular Ca2+ and Na+ of 
the rodent myocyte [18]; and there is the more recent 
evidence [28] showing that in transgenic mice with car-
diac-specific overexpression of α2 isoform, but not in 
mice with overexpression of α1 isoform, TAC-induced 
hypertrophy and remodeling are attenuated. While a 
Con









































































































































Fig. 6 Effects of ouabain on TAC-induced cardiac dysfunction in Con and p85-KO mice. Experiments were done as described in “Methods”. Left 
ventricular cardiac functions were monitored by echocardiography before and after 8 weeks of the TAC or sham surgery. Ouabain was infused sub-
cutaneously (50 μg/kg/day) by ALZET osmotic pumps for continuous dosing for the first 4 weeks. a Fraction shortening, FS % in Con and KO mice. b 
representative echocardiographic M-mode views of mouse left ventricles at week 8 after surgery. c myocardial performance index (MPI) in Con and 
KO mice. d representative Pulsed-Wave Doppler flow used for MPI calculation. n = 6 ~ 7, *P < 0.05 vs. Sham; #P < 0.05 vs. TAC
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thorough examination of the relation of our findings to 
those of Correll et  al. [28] is outside the scope of this 
Discussion, we suggest that the findings of the two labo-
ratories are supportive of each other in emphasizing the 
need for further studies on how the α2 isoform regu-
lates TAC-induced pathological hypertrophy on the one 
hand, and ouabain-induced activation of PI3Kα on the 
other.
Our results indicating that in the control mouse the 
prophylactic effect of nontoxic ouabain concentrations 
on the pressure overloaded heart is due to the drug’s 
interaction with the α2 isoform of cardiac Na+/K+-
ATPase is also significant when we consider the possible 
relevance of the present animal studies to the therapeu-
tic use of digitalis in man. Because all cardiac α isoforms 
of Na+/K+-ATPase in the human heart have high digi-
talis sensitivities similar to the α2-isoform of the rodent 
heart [8], it is reasonable to suspect that low nM blood 
levels of ouabain or another digitalis drug may also exert 
similar prophylactic effects in man without disturbing 
intracellular ion concentration. Whether only the human 
α2-isoform or all three human cardiac isoforms respond 
to subinotropic ouabain concentrations through the acti-
vation of PI3Kα remains to be investigated.
Regarding the potential relevance of the present find-
ings to the clinical use of digitalis, our findings also 
suggest the following possibility: Since numerous reex-
aminations of the Digitalis Investigation Group trial [29, 
30] have indicated the beneficial effects of lower serum 
levels of digoxin (0.64–1.15 nM) resulting from the dos-
age used in the trial, it may be that such therapeutic ben-
efits were induced through the selective activations of 
PI3Kα and the signaling cascades that are linked to this 
lipid kinase rather than by safe levels of digoxin-induced 
positive inotropy. Though it is most commonly assumed 
that any beneficial effect of digitalis in the treatment of 
heart failure is due to the drug’s positive inotropic action, 
it is appropriate to recall that there has never been a con-
sensus on this issue, especially in studies on man [30–32].
Conclusion
This study establishes that in normal mice low and safe 
doses of ouabain, a prototypic digitalis drug, prevent or 
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Fig. 7 Effects of ouabain on TAC-induced heart weight, cardiac fibrosis and pathological hypertrophic markers after 8 weeks of surgery. a Repre-
sentative heart images (left) and quantitative heart weights (right); b representative images (left) and quantitative data (right) on cardiac fibrosis by 
trichrome staining (n = 5) and c fetal genes ANP, BNP mRNA expression in Con and p85-KO hearts. n = 6 ~ 7, *P < 0.05 vs. Sham; #P < 0.05 vs. TAC
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pressure overload on the heart. Our findings also show 
that these ouabain effects are exerted through its binding 
to the α2-isoform of the mouse cardiac Na+/K+-ATPase, 
and the resulting activation of PI3Kα/Akt cell signal-
ing cascades. Also clearly indicated by our results is that 
the known downregulation of the cardiac α2-isoform by 
pressure overload is prevented by ouabain-induced acti-
vation of PI3Kα. In conjunction with a wealth of available 
information on the clinical use of digitalis drugs in man, 
the present findings also suggest the need for further 
studies on the potential use of these drugs for the preven-
tion of heart failure as advocated nearly a century ago.
Methods
Animal
Adult male mice of 2–6 months of age were used for this 
study. PI3K p85αloxP/loxP p85β−/− mice were gifts from 
Luo et  al. [16]. Striated muscle creatine kinase (mck)-
Cre transgenic mice (control mice; also referred to as 
“Con” mice) were purchased from the Jackson Labora-
tory (Stock #006475). PI3K p85α muscle-specific knock-
out p85β global knockout mice (p85αmKO p85β−/− mice, 
referred to as “p85-KO” mice) were crossbred by PI3K 
p85αloxP/loxP p85β−/− mice with mck-Cre mice. All mice 
were housed in pathogen-free conditions and maintained 
with 12  h dark/light cycle with free access to food and 
water. Animal care and experiments were done following 
the guidelines of NIH guide for the care and use of labo-
ratory animals and the Institutional Animal Care and Use 
Committee of the University of Toledo.
Adult mouse cardiomyocyte isolation and culture
12–16  week old male mice were used for isolation and 
culture of cardiomyocytes as previously described [14, 
26]. Mice were heparinized (5000 U/Kg) and anesthe-
tized with Ketamine (200  mg/kg b.w.)/Xylazine (10  mg/
kg b.w.) via intraperitoneal (i.p.) injection. Approxi-
mately, 1.0 million viable rod-shaped cells were yielded 
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Fig. 8 Effects of ouabain on TAC-induced changes on Na+/K+-ATPase (NKA) isoforms in Con and KO hearts after 8 weeks of surgery. a Representa-
tive blots (top) and quantitative data (bottom) of protein expression of NKA α1 and α2 in Con hearts; b representative blots (top) and quantitative 
data (bottom) of protein expression of NKA α1 and α2 in p85-KO hearts; c mRNA expression of NKA α2 in Con hearts and d mRNA expression of NKA 
α2 in KO hearts. n = 6 ~ 7, *P < 0.05 vs. Sham, #P < 0.05 vs. TAC
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from one heart. Cardiomyocytes were seeded to the cul-
ture dishes (pre-coated with 10 μg/ml laminin) in Modi-
fied Eagle’s Medium, supplemented with 2  mM ATP, 
2 mM glutamine, 10 % fetal bovine serum (FBS), 10 mM 
2,3-butanedione monoxime (BDM), 100 U/ml penicillin 
and 100 μg/ml streptomycin for 2 h in a 2 % CO2 humidi-
fied incubator and then cultured overnight in a medium 
in which FBS was replaced by 0.1 % Bovine Serum Albu-
min. This medium was then changed to a fresh one that 
excluded BDM 30  min before the start of the indicated 
experiments.
SDS‑PAGE/western blot analysis
This was done as described before [13, 33]. Briefly, pro-
tein was extracted from cultured cardiomoycytes or 
homogenized cardiac ventricular tissue in RIPA buffer. 
Protein extracts (10-80 µg) were combined with Laemmli 
loading buffer containing 5 % 2-mercaptoethanol, boiled 
for 5 min, and size fractionated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS PAGE). 
When extracts were to be subjected to SDS-PAGE for 
the detection of Na+/K+-ATPase subunits, they were 
incubated at 37 °C for 15–30 min instead of being boiled. 
Proteins were transferred to Polyvinylidene Difluoride 
membranes. Membranes were incubated for 1  h with 
5 % nonfat dried milk in Tris-Buffered Saline Tween-20 
buffer and then incubated overnight at 4 °C with primary 
antibodies. After incubation, membranes were washed, 
incubated with peroxidase-conjugated secondary anti-
body, and analyzed using ECL (Perkin-Elmer Life Sci-
ences). Primary antibodies were from BD Transduction 
Laboratories: anti-PI3  K p110α, anti-PI3  K p85; Cell 
Signaling Technology: rabbit anti-phospho 473-Akt, anti-
Akt; Developmental Studies Hybridoma Bank, Univer-
sity of Iowa (Iowa City, IA): Na+/K+-ATPase α1 (α6F); 
ABR: Na+/K+-ATPase α2; Millipore: Na+/K+-ATPase β1. 
Anti-PI3  K p110γ, GAPDH, secondary antibodies goat 
anti-rabbit IgG-horseradish peroxidase (HRP), and goat 
anti-mouse IgG-HRP were purchased from Santa Cruz 
Biotechnology.
PI3 K lipid kinase assay
This was conducted as previously described [13, 14, 
33]. Briefly, cells were lysed in RIPA buffer with inhibi-
tors. Equal amount of protein in each sample were incu-
bated with either anti-PI3  K p85α antibody (06–195, 
EMD Millipore), or anti-PI3 K p110γ antibody (sc-7177, 
Santa Cruz) overnight at 4  °C, followed by incubation 
with Protein A agarose beads for 3 h at 4  °C. And then, 
the immune complex was washed four times with buffer 
(100  mM NaCl, 1  mM Na3VO4, and 20  mM HEPES, 
pH 7.5) and resuspended in 40  µl of buffer (180  mM 
NaCl and 20 mM HEPES, pH 7.5). PI3 K activity in the 
immunoprecipitates was assayed directly on the beads 
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Fig. 9 Schematic presentation of ouabain’s different growth-related effects on α1 and α2 isoforms of Na+/K+-ATPase in the mouse cardiomyocytes. 
a α2-isoform: activation by sub-inotropic ouabain concentrations (< 40 nM) of the signaling cascades that lead to physiological hypertrophy, and 
block TAC-induced pathological hypertrophy and b α1-isoform: induction of positive inotropy by higher concentrations of ouabain, and activation 
of signaling cascades that leads to pathological hypertrophy and cell death. See “Discussion”
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by a standard procedure with PI 0.6 mg/ml (Avanti Polar 
Lipids, Alabaster, AL, USA) and [γ-32P] ATP (250  μM) 
used as substrates. The reactions were performed at room 
temperature and stopped after 10  min by addition of 
80 µl of 1 M HCl. The lipids were extracted with 160 µl of 
chloroform–methanol (1:1), spotted on a thin-layer chro-
matography plate, and separated with chloroform-ace-
tone-methanol-glacial acetic acid-H2O (40:15:13:12:8). 
The reaction product [γ-32P] PI(3)P was separated from 
the origin on the TLC plate and was exposed to storage 
phosphor screen. The screen was scanned by Typhoon 
Trio phosphorimager (GE Healthcare, USA) and the top 
PI(3)P dots were quantified by Image J software.
Protein synthesis assay
Protein synthesis was measured using [3H]-Leucine or 
[3H]-Phenylalanine incorporation assay as previously 
described [14, 33]. Protein synthesis assay was used as 
indication of myocyte hypertrophy [14].
Real‑time reverse transcription polymerase chain reaction 
(RT‑PCR)
This was conducted as previously described [14]. Total 
RNAs were extracted from cardiomyocytes and heart 
tissues with RNeasy plus mini kit (Qiagen, #74134) and 
RNeasy Fibrous Tissue Kit (Qiagen, #74704) respectively 
according to the manufacturer’s instructions. High-
capacity cDNA reverse transcription kit (AB applied 
Biosystems) was used for RT-PCR. Real-time PCR was 
performed by the SYBR Green method with an Applied 
Biosystems 7500 Fast Real-Time PCR System. All sam-
ples were run in triplicate. In all cases, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene was used for 
data standardization and normalization. Gene expression 
levels and fold change comparisons were assessed using 
the ΔCt (cycle threshold) and ΔΔCt, respectively. Prim-
ers (forward and reverse, 5′ → 3′) were ANP: TCG TCT 
TGG CCT TTT GGC T and TCC AGG TGG TCT AGC 
AGG TTC T; BNP: AAG TCC TAG CCA GTC TCC AGA 
and GAG CTG TCT CTG GGC CAT TTC; β-MHC: ATG 
TGC CGG ACC TTG GAA G and CCT CGG GTT AGC 
TGA GAG ATC A; NKA α1: ATC TGA GCC CAA ACA 
CCT GCT AGT and AAG CGT CCT TCA GCT CTT 
CAT CCA; NKA α2: ACA ACC AGA TCC ATG AGG 
CTG ACA and TTG AGC AGA GCT GAC TAC GAA 
GCA; and GAPDH: CAT GGC CTT CCG TGT TCC TA 
and CCT GCT TCA CCA CCT TCT TGA T.
TAC surgery and osmotic mini‑pump implantation
Microsurgical procedure of pressure overload hypertro-
phy induced through TAC was performed by modifica-
tion of previously described procedures [34, 35]. Briefly, 
12 week-old male mice were anesthetized with isoflurane 
5 % and connected to a rodent ventilator. The chest cav-
ity was entered through sternum above the third rib, and 
aortic constriction was performed by tying a 6–0 silk 
suture (SP114, LOOK™ suture) against a 27 gauge needle 
for Con mice or a 25 gauge needle for KO mice, resulting 
in similar degrees of hypertrophy in both groups (Addi-
tional file 1: Fig. S2). Sham operated mice underwent the 
same operation except for tying the suture loosely. We 
noted that aortic constriction by a 27-gauge needle on 
KO mice caused 100 % mortality but all mice survived in 
sham group. For pain relief, a subcutaneous injection of 
buprenorphine (0.05–0.1  mg/kg) was administered for 
each mouse.
Ouabain-filled osmotic mini-pumps (Alzet, #2004) 
were implanted underneath the dorsal skin 1 day after the 
surgery under anesthesia by 2–3  % isoflurane. Ouabain 
(50 μg/kg/day) was continuously infused for 4 weeks. All 
mice were euthanized at the end of 8 weeks after surgery. 
Body weight and heart weight were recorded. One part of 
ventricular free wall was immediately fixed for histologi-
cal study; the rest of left ventricles were snap-frozen in 
liquid nitrogen and stored in −80 °C for further analyses.
Mice were subjected to euthanasia by administration of 
ketamine (200 mg/kg b.w.) and xylazine (10 mg/kg b.w.) 
i.p. at the end of the experiment.
Echocardiography
Left ventricular function and geometry was assessed as 
previously described [36]. Briefly, mice underwent echo-
cardiographic assessment using an ACUSON Sequoia ™ 
C512 Ultrasound System (Siemens) with a 15-MHz linear 
array transducer. The mice were anesthetized with iso-
flurane (2 %) in 100 % oxygen in an anesthesia chamber. 
Anesthesia was maintained (0.5–1.5 %) by mask. Anesthe-
tized mice were weighed, de-haired, transferred to a heat-
ing pad, and placed in a supine position. The parasternal 
long axis was used to obtain 2-D and 2-D guided M-mode 
images for the assessment of LV end systolic and diastolic 
areas, diameters, wall thicknesses and systolic function. 
Transmitral Doppler flow was traced in parasternal long 
axis view for measurement of left ventricular isovolumet-
ric contraction time (IVCT), isovolumetric relaxation 
time (IVRT) and ejection time (ET). Myocardial Perfor-
mance Index (MPI), which reflects both cardiac diastolic 
and systolic function, was calculated by the following 
equation: MPI = (IVCT + IVRT)/ET.
Catheterization of mouse left ventricles
The procedure was conducted under a stereomicro-
scope according to the published protocol [37]. Mice 
were heparinized (5000 U/kg) and anesthetized with 
Ketamine (50–150  mg/kg) and Xylazine (2.5–7.5  mg/
kg) via intraperitoneal (i.p.) injection. Mice were placed 
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on the surgical platform and kept warm at 37 °C. MPVS 
UltraTM Pressure–Volume (P–V) system (Millar Instru-
ments, Inc.) and PowerLab 8/30 (ADInstruments, 
Inc.) were turned on for stabilization 30  min prior to 
the recording. The mouse Pressure–Volume conduct-
ance catheter (SPR-839, Millar Instruments, Inc.) was 
advanced into the left ventricle through right carotid 
artery. After stabilization of the signal for 10–15 min, the 
pressure and volume signals (P–V loops) were acquired 
and recorded by PowerLab 8/30 (ADInstruments, Inc.) 
and MPVS UltraTM Pressure–Volume (P–V) system 
(Millar Instruments, Inc.). Real-time P–V loop and other 
cardiac functions (e.g. HR, dp/dt, etc.) were monitored 
and data analysis was conducted with Labchart 7 (ADIn-
struments, Inc.) software.
Masson trichrome staining
Left ventricle was fixed in 10  % buffered formalin con-
ducted by the standard Masson’s trichrome staining 
procedure. The staining was shown as nuclei (black), 
cytoplasm, muscle fibers (red) and collagen (blue). 
Images were taken by the Olympus IX51 inverted micro-
scope connected to SPOT Insight 2.0 Mp Camera under 
a 20 × objective lens. Seven-fourteen pictures were taken 
from each heart sample. The percentage of blue area in 
each heart section was quantified by Image J software 
(National Institutes of Health, USA).
Data analysis
All data are presented as mean ± standard error. Statis-
tical analyses were performed by using GraphPad Prism 
5.0 software (La Jolla, CA, USA). The Student’s t test was 
used to compare two groups. One-way analysis of vari-
ance (ANOVA), followed by the Bonferroni’s post hoc 
test was used to compare multiple groups. Other method 
was listed in the figure legend. Differences were consid-
ered statistically significant at p < 0.05.
Additional file
Additional file 1: Figure S1. Effect of ouabain infusion on systemic 
blood pressure in Con and p85-KO mice. Mice were grouped as sham, 
sham+oua (50 μg/kg/day b.w.), TAC or TAC+oua (50 μg/kg/day b.w.). 
Ouabainfilled osmotic mini-pumps (Alzet, #2004) were implanted under-
neath the dorsal skin one day after the surgery. Ouabain (50 μg/Kg/day) 
was continuously infused for 4 weeks. All mice were euthanized at the 
end of 8 weeks after surgery. Blood pressure was measured by tail-cuff 
volume-pressure recording (VPR) every two weeks. A. Con: sham (n=7), 
sham+oua (n = 6), TAC (n = 7), TAC+oua (n = 6); B. p85-KO: sham (n = 5), 
sham+oua (n = 4), TAC (n = 4), TAC+oua (n = 6). Figure S2. Comparison 
of TAC-induced cardiac hypertrophy in Con and p85-KO mice. Experi-
ments were done as described in Methods. Left ventricular wall thickness 
was monitored by echocardiography before and after eight weeks of the 
surgery. A. Relative wall thickness (RWT). n = 6~7, * P < 0.05 v.s. Sham; B. 
Comparison of TAC-induced hypertrophy between Con and p85-KO mice. 
There is no difference between two groups by repeated measures ANOVA. 
* P < 0.05.
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